Cover Image
市場調查報告書

Adamas Pharmaceuticals, Inc.的產品平台分析

Adamas Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226291
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
Adamas Pharmaceuticals, Inc.的產品平台分析 Adamas Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 37 Pages
簡介

Adamas Pharmaceuticals, Inc.是美國的製藥企業,正在開發著帕金森氏症上以左旋多巴誘導性異動症為首的中樞神經系統疾病的治療藥。

本報告提供Adamas Pharmaceuticals, Inc. 的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Adamas Pharmaceuticals, Inc. 概要

  • 公司概要
  • 主要資訊
  • 企業資料

Adamas Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Adamas Pharmaceuticals, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Adamas Pharmaceuticals, Inc. :開發中產品概況

  • 後期階段產品開發中產品
    • 新藥登記前階段的產品/聯合治療模式
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

Adamas Pharmaceuticals, Inc. :藥物簡介

  • memantine hydrochloride ER + donepezil hydrochloride
  • amantadine hydrochloride ER
  • ADS-8800 Series
  • ADS-9000 Series

Adamas Pharmaceuticals, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Adamas Pharmaceuticals, Inc. :最近的開發平台趨勢

Adamas Pharmaceuticals, Inc. :暫停中的計劃

Adamas Pharmaceuticals, Inc. :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07451CDB

Summary

Global Markets Direct's, 'Adamas Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Adamas Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Adamas Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Adamas Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Adamas Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Adamas Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Adamas Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Adamas Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Adamas Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Adamas Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Adamas Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Adamas Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Adamas Pharmaceuticals, Inc. Snapshot
    • Adamas Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Adamas Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Adamas Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Adamas Pharmaceuticals, Inc. - Pipeline Products Glance
    • Adamas Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Adamas Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Adamas Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Adamas Pharmaceuticals, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Adamas Pharmaceuticals, Inc. - Drug Profiles
    • amantadine hydrochloride ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (amantadine hydrochloride + oseltamivir phosphate + ribavirin)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADS-4000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADS-8800
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADS-9000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADS-324
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (memantine hydrochloride ER + donepezil hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Adamas Pharmaceuticals, Inc. - Pipeline Analysis
    • Adamas Pharmaceuticals, Inc. - Pipeline Products by Target
    • Adamas Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Adamas Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Adamas Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Adamas Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Adamas Pharmaceuticals, Inc. - Dormant Projects
  • Adamas Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Adamas Pharmaceuticals, Inc., Key Information
  • Adamas Pharmaceuticals, Inc., Key Facts
  • Adamas Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Adamas Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Adamas Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Adamas Pharmaceuticals, Inc. - Phase III, 2015
  • Adamas Pharmaceuticals, Inc. - Phase II, 2015
  • Adamas Pharmaceuticals, Inc. - Preclinical, 2015
  • Adamas Pharmaceuticals, Inc. - Discovery, 2015
  • Adamas Pharmaceuticals, Inc. - Unknown, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Adamas Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Adamas Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Adamas Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Adamas Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Adamas Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Adamas Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top